STOCK TITAN

INmune Bio Inc - INMB STOCK NEWS

Welcome to our dedicated news page for INmune Bio (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INmune Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INmune Bio's position in the market.

Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company focuses on targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with XProTM. The presentation will be held virtually on February 14, 2024, by the CEO, RJ Tesi, M.D., and CFO, David Moss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences
-
Rhea-AI Summary
INmune Bio, Inc. announces participation in Baird’s Biotech Discovery Series webcast to discuss ongoing Phase II trial for Early Alzheimer's disease and Phase I trial data, featuring key speakers and registration details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
conferences
-
Rhea-AI Summary
INmune Bio Inc. (INMB) has received confirmation from the FDA that the full clinical hold on the Company’s Alzheimer’s disease (AD) clinical trial program has been lifted. The Phase II trial is on track to enroll the last patient mid-2024, with top line data expected approximately six months after the last patient is enrolled. CEO RJ Tesi expressed satisfaction with the FDA's response and outlined the company's goals for the Phase III AD program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) dosed the first patient in the Phase I/II trial for INKmune™, a biologic therapy for metastatic castration-resistant prostate cancer (mCRPC), on December 27, 2023. The therapy aims to harness the patient’s innate immune system to fight disease, with promising potential in targeting NK cells abundant in the tumor microenvironment. Professor Matt Rettig, a leading expert, expressed optimism in this novel strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
clinical trial
-
Rhea-AI Summary
INmune Bio Inc. (NASDAQ: INMB) is accelerating enrollment in its Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation outside the US, maintaining its timeline for the trial. However, the Phase II study remains on clinical hold in the US pending additional information on long-term stability, with the Company expecting to provide the necessary data before the end of 2023. The Company is on track to complete enrollment of its Phase II clinical trial in patients with early Alzheimer’s Disease and biomarkers of inflammation in 2024. The trial is open in Australia, Canada, the United Kingdom, Poland, France, Spain, and is expected to open soon in several additional EU countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
clinical trial
-
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) presents data on the use of INB03, a dominant-negative TNF inhibitor, to improve the potency of trastuzumab deruxtecan (T-DXd, ENHERTU®) in the treatment of high-risk MUC4 expressing HER2 positive breast cancer. The work demonstrates that INB03 decreases resistance to T-DXd therapy in three ways, suggesting that it may allow for lower doses of T-DXd to be effective in women with MUC4 expressing HER2+ breast cancer and improve the response to T-DXd in women with resistant HER2+ disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
Rhea-AI Summary
INmune Bio, Inc. (INMB) has received authorization from the European Medicines Agency (EMA) to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™. The trial is currently enrolling patients in Australia, Canada, the United Kingdom, France, and Spain. The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer's disease who have biomarkers of elevated inflammation. In a prior Phase I open-label trial, INmune Bio met all primary and secondary endpoints. Patients with AD who received XPro™ demonstrated notable decreases in neuroinflammation, enhanced axonal integrity, and improved synaptic function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
clinical trial
-
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) has received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional EU countries expected to open soon. The company also received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
clinical trial
-
Rhea-AI Summary
INmune Bio Inc. announces Q3 2023 financial results and provides business update. Highlights include authorization to initiate a Phase II trial for XPro™ in Early Alzheimer's Disease, expansion of MRI biomarker data, and positive preclinical data for INB03. Net loss for Q3 2023 was $8.6 million. The company had cash and cash equivalents of $41.8 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
earnings
Rhea-AI Summary
INmune Bio, Inc. receives a favorable patentability opinion for its international patent application covering its proprietary cell line, INB16, and the therapeutic composition INKmune™. The application contains patentable subject matter and explores potential commercial applications in cancer research and treatment. The company plans to leverage the opinion to accelerate examination and patent issuance. INB16 is a tumor cell line that can prime natural killer (NK) cells to enhance their ability to fight cancer. The company has safely treated five patients with hematological cancers using INKmune™ and plans to initiate a US trial in metastatic castration-resistant prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.84%
Tags
none
INmune Bio Inc

Nasdaq:INMB

INMB Rankings

INMB Stock Data

236.26M
11.73M
34.92%
13.84%
6.52%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boca Raton

About INMB

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.